BACKGROUND: Resistance to an immune checkpoint inhibitor (ICI) is a major obstacle in cancer immunotherapy.
Publications
Complete remission in metastatic primary malignant melanoma of the esophagus with nivolumab: a case report
Primary malignant melanoma of the esophagus is a rare form of mucosal melanoma with a poor prognosis.
Bempegaldesleukin plus nivolumab in first-line metastatic melanoma
In this phase II cohort from the international, single-arm PIVOT-02 study, researchers sought to assess the CD122-preferential interleukin-2 pathway agonist bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) in first-line metastatic melanoma.
Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors
The clinical and immunologic implications of the SARS-CoV-2 pandemic for patients with cancer receiving systemic anticancer therapy have introduced a multitude of clinical challenges and academic controversies.